Astellas Balks On Vibativ License, But Focus Shifts To Tivozanib And MDV3100
This article was originally published in PharmAsia News
Executive Summary
Astellas terminates Vibativ license after just one year on the market to allocate resources for urology and transplantation while focus shifts to Phase III oncology drugs.